Immune checkpoint blocking antibodies targeting the PD-1 and PD-L1 pathways show encouraging results for inducing HCC remissions and imply HCC tumors are immunogeneic (Greten and Sangro, 2017; Okusaka and Ikeda, 2018). The gene discussed is CD274; the disease is hepatocellular carcinoma.